FLOW SUMMARY

Sentiment on Arrowhead Pharmaceuticals (ARWR) is currently dominated by a speculative BULLISH bias, as evidenced by a Put/Call Ratio of 0.61 for the August 21, 2026 expiration, indicating a clear predominance of call volumes (370) over puts (225). This suggests risk appetite and an anticipation of upside from options market participants. However, institutional activity in dark pools remains moderate, with an OTC volume of 732,874 shares and a notional value of $0.02 billion over the past week, indicating low participation from large funds via these channels. Combining these elements, the aggregated sentiment bias is POSITIVE, although the low dark pool activity tempers the purely speculative enthusiasm from options.

TECHNICAL AND VOLUMETRIC STRUCTURE

ARWR is currently trading at $89.26, showing an intraday gain of +2.34%. The technical structure is BULLISH, with the price trading above its 20-day moving average (SMA20) at $81.08 and its 200-day moving average (SMA200) at $65.69, confirming a positive underlying trend. The RSI(14) is high at 74.70, signaling strong but potentially extended technical momentum. The asset is at 92% of its 52-week range, approaching its key 6-month resistance level at $95.49. Today's volume stands at 1,028,007 shares, representing 46% of its monthly average, indicating moderate buying pressure without excessive volume. Over the past 14 days, ARWR has recorded a notable performance of +25.1%, suggesting that a significant portion of positive news has already been priced in. The 6-month resistance at $95.49 represents an immediate target, while the 1-month support is established at $69.88.

SCENARIOS & MACROECONOMIC CATALYSTS

On the primary horizon (medium term, 20-60 days):

BULLISH SCENARIO (57% probability): ARWR continues its advance towards the analyst consensus of $108.09, driven by quarterly results exceeding expectations and confirmation of optimism surrounding the plozasiran data. The current BULL market regime (SPY > MA50 > MA200) and a VIX of 16.35 (risk-on) provide a favorable macro environment. The asset's 3-month outperformance (+9.0% vs SPY) validates its structural relative strength. Catalysts include the release of solid earnings, announcements of further clinical or regulatory progress for plozasiran, and sustained risk appetite in biotechnology.

BASE SCENARIO (28% probability): The stock consolidates around the $95.49 resistance after the earnings release, lacking major catalysts to justify an immediate break towards the consensus. The strong 14-day rally (+25.1%) and the high RSI (74.70) limit immediate upside potential, as the market is already pricing in a large portion of the good news. Persistent moderate macro risk (overall score at 55/100, with high geopolitical, energy, and monetary risks) could dampen momentum.

BEARISH SCENARIO (15% probability): The stock experiences post-earnings profit-taking, or the results disappoint the market's high expectations. A close below the SMA20 ($81.08) or a deterioration in the overall macroeconomic sentiment (e.g., inflation resurgence, rising rates) could lead to a pullback towards the $69.88 support. High geopolitical and monetary risks, although moderated by the overall score, could exacerbate a negative reaction.

AEGIS VERDICT

In a BULL regime (SPY above its moving averages), this BULLISH signal on ARWR is based on optimism surrounding the plozasiran data and the potential for post-earnings revaluation. Macro risk remains MODERATE, but geopolitical and monetary tensions require increased vigilance. The R/R ratio of 3.62:1 is favorable. The signal triggers on a daily close above $90.00. The first target (TP1) is set at $95.49, and the final target (TP2) at $108.09. Recommended sizing: Reduced position (0.5x), considering the already significant momentum and the asset's proximity to its annual highs. Invalidation catalysts include a close below $85.00, earnings below expectations, or a marked deterioration in general market sentiment.